CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.

The contract, though sizable, is likely immaterial to CVS’ earnings. But it moves the company in a positive direction as it ...

A lawsuit filed in federal court on behalf of the University of Pennsylvania and its health system alleges that 20 years of skyrocketing prices on drugs that treat diabetes, like insulin, can be ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

For CVS, Q2 earnings will be a critical inflection point. A miss could trigger a breakup or further decline, making the stock ...

CVS Health has secured a major healthcare deal, winning a multi-year pharmacy benefits contract with CalPERS, outbidding rival UnitedHealth. The deal marks a significant win for CVS's Caremark unit ...

Omada Health (OMDA) is a strong buy. Backed by 29 studies, key partnerships with Cigna and CVS drive growth, credibility, and ...

NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Litigation over state power to regulate pharmacy benefit managers is far from over, even after the US Supreme Court bolstered ...

Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...